Journal of Clinical Endocrinology & Metabolism, Vol 80, 869-874, Copyright © 1995 by Endocrine Society

ARTICLES

Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect

N Mauras and B Beaufrere
Nemours Children's Clinic, Jacksonville, Florida 32207.

To investigate whether recombinant human insulin-like growth factor-I (rhIGF-I) could serve as a protein-sparing nondiabetogenic agent, 21 healthy volunteers (mean age, 25 +/- 1 yr) were studied in 3 similar clinical models: rhIGF-I alone, rhIGF-I and prednisone, and prednisone alone. In study A, 6 subjects received infusions of [14C]leucine and [2H2]glucose before and after 5-7 days of rhIGF-I (100 micrograms/kg, sc, twice daily, followed by 16 h of a 10 micrograms/kg.h continuous sc infusion). The rate of appearance (Ra) of leucine, an estimate of whole body proteolysis, did not change significantly, whereas leucine oxidation decreased (-31 +/- 4%; P = 0.001), hence the nonoxidative leucine disposal (NOLD) increased significantly (P = 0.04). These effects are similar to those reported with high dose hGH. Plasma glucose concentrations did not change despite a significant reduction in circulating insulin concentrations (-58 +/- 11%; P = 0.01) and an increase in the glucose Ra (+12 +/- 5%; P = 0.04). After rhIGF-I treatment, plasma IGF-I, IGF-binding protein-1 (IGFBP-1), and IGFBP-2 all increased significantly, whereas IGFBP-3 did not change. In study B, seven subjects received rhIGF-I combined with oral prednisone (0.8 mg/kg.day) for 5 days. Group C (n = 8) received only prednisone. In group B, both the leucine Ra and oxidation increased (Ra, +7 +/- 3%; oxidation, +45 +/- 13%), but this increase was significantly less than that seen in group C (Ra, +25 +/- 5%; oxidation, 117 +/- 17%; P < 0.005 vs. group B). Group B showed no significant changes in postabsorptive glucose concentrations despite marked reductions in circulating insulin levels, in contrast to the increase in insulin and glucose concentrations observed in group C. In conclusion, 100 micrograms/g rhIGF-I, given twice daily, 1) has GH-like effects on whole body protein metabolism, 2) markedly diminishes the protein catabolic effect of glucocorticosteroids, and 3) is nondiabetogenic in prednisone- treated humans. This agent offers promise in the treatment of protein catabolic states.

This article has been cited by other articles:

				P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, S. Yakar, and D. LeRoith Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus Endocrinology, June 1, 2006; 147(6): 2619 - 2630. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				K. R. Short, J. Nygren, M. L. Bigelow, and K. S. Nair Effect of Short-Term Prednisone Use on Blood Flow, Muscle Protein Metabolism, and Function J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6198 - 6207. [Abstract] [Full Text] [PDF]

				D. S. Hardin, K. J. Ellis, M. Dyson, J. Rice, R. McConnell, and D. K. Seilheimer Growth Hormone Decreases Protein Catabolism in Children with Cystic Fibrosis J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4424 - 4428. [Abstract] [Full Text] [PDF]

				V. Y. Hayes, R. J. Urban, J. Jiang, T. J. Marcell, K. Helgeson, and N. Mauras Recombinant Human Growth Hormone and Recombinant Human Insulin-Like Growth Factor I Diminish the Catabolic Effects of Hypogonadism in Man: Metabolic and Molecular Effects J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2211 - 2219. [Abstract] [Full Text]

				N. Mauras, V. Martinez, A. Rini, and J. Guevara-Aguirre Recombinant Human Insulin-Like Growth Factor I Has Significant Anabolic Effects in Adults with Growth Hormone Receptor Deficiency: Studies on Protein, Glucose, and Lipid Metabolism J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3036 - 3042. [Abstract] [Full Text]

				N. Mauras, K. O. O’Brien, S. Welch, A. Rini, K. Helgeson, N. E. Vieira, and A. L. Yergey Insulin-Like Growth Factor I and Growth Hormone (GH) Treatment in GH-Deficient Humans: Differential Effects on Protein, Glucose, Lipid, and Calcium Metabolism J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1686 - 1694. [Abstract] [Full Text]

				N. Mauras, V. Quarmby, and D. C. Bloedow Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins Am J Physiol Endocrinol Metab, October 1, 1999; 277(4): E579 - E584. [Abstract] [Full Text] [PDF]

				N. Mauras, V. Hayes, S. Welch, A. Rini, K. Helgeson, M. Dokler, J. D. Veldhuis, and R. J. Urban Testosterone Deficiency in Young Men: Marked Alterations in Whole Body Protein Kinetics, Strength, and Adiposity J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1886 - 1892. [Abstract] [Full Text]

				A. W. Bell, D. E. Bauman, D. H. Beermann, and R. J. Harrell Nutrition, Development and Efficacy of Growth Modifiers in Livestock Species J. Nutr., February 1, 1998; 128(2): 360 - 360. [Abstract] [Full Text]

				K. Berneis, R. Ninnis, J. Girard, B. M. Frey, and U. Keller Effects of Insulin-Like Growth Factor I Combined with Growth Hormone on Glucocorticoid-Induced Whole-Body Protein Catabolism in Man J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2528 - 2534. [Abstract] [Full Text] [PDF]

				R. Clark The Somatogenic Hormones and Insulin-Like Growth Factor-1: Stimulators of Lymphopoiesis and Immune Function Endocr. Rev., April 1, 1997; 18(2): 157 - 179. [Abstract] [Full Text]

				J.-P. Thissen and J. Verniers Inhibition by Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} of the Insulin-Like Growth Factor I Messenger Ribonucleic Acid Response to Growth Hormone in Rat Hepatocyte Primary Culture Endocrinology, March 1, 1997; 138(3): 1078 - 1084. [Abstract] [Full Text] [PDF]